MD1406Z - Method for treating inflammatory diseases of periodontium and oral mucosa - Google Patents
Method for treating inflammatory diseases of periodontium and oral mucosa Download PDFInfo
- Publication number
- MD1406Z MD1406Z MDS20190050A MDS20190050A MD1406Z MD 1406 Z MD1406 Z MD 1406Z MD S20190050 A MDS20190050 A MD S20190050A MD S20190050 A MDS20190050 A MD S20190050A MD 1406 Z MD1406 Z MD 1406Z
- Authority
- MD
- Moldova
- Prior art keywords
- periodontium
- oral mucosa
- inflammatory diseases
- treating inflammatory
- treatment
- Prior art date
Links
- 210000002200 mouth mucosa Anatomy 0.000 title claims abstract description 10
- 210000004261 periodontium Anatomy 0.000 title claims abstract description 6
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 5
- 238000000034 method Methods 0.000 title claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 8
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims abstract description 6
- 239000005708 Sodium hypochlorite Substances 0.000 claims abstract description 4
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 210000004877 mucosa Anatomy 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 4
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 208000028169 periodontal disease Diseases 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010006326 Breath odour Diseases 0.000 description 4
- 206010018276 Gingival bleeding Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 4
- 208000005888 Periodontal Pocket Diseases 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000003433 Gingival Pocket Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000005562 gingival recession Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 208000008887 Dental Deposits Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010070648 Pyridoxal Kinase Proteins 0.000 description 1
- 102100038517 Pyridoxal kinase Human genes 0.000 description 1
- 208000009596 Tooth Mobility Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001909 alveolar process Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Invenţia se referă la medicină, în special la stomatologie şi poate fi utilizată pentru tratamentul afecţiunilor inflamatorii ale parodonţiului şi mucoasei cavităţii bucale. The invention relates to medicine, in particular to dentistry, and can be used for the treatment of inflammatory diseases of the periodontium and the oral mucosa.
Este cunoscută metoda de tratament al afecţiunilor inflamatorii ale parodonţiului, care constă în prelucrarea ţesuturilor cavităţii bucale prin spălături sau irigări cu soluţie apoasă sau cu soluţie fiziologică, care conţine amestec de ozon şi oxigen, timp de 2…5 zile cu o cantitate de 50…150 mL, amestecul de ozon şi oxigen obţinându-se prin barbotarea în apă sau soluţie fiziologică a ozonului şi oxigenului cu viteza curentului de 1 L/min, timp de 8…10 min, unde concentraţia ozonului este de 2000 µg/L [1]. The method of treating inflammatory periodontal diseases is known, which consists of processing the tissues of the oral cavity by washing or irrigation with an aqueous solution or physiological solution containing a mixture of ozone and oxygen, for 2…5 days with a quantity of 50…150 mL, the mixture of ozone and oxygen being obtained by bubbling ozone and oxygen in water or physiological solution with a flow rate of 1 L/min, for 8…10 min, where the ozone concentration is 2000 µg/L [1].
De asemenea, este cunoscută metoda de tratament al afecţiunilor parodonţiului, ce include administrarea unui complex de preparate medicamentoase - tripsină, teritilină, furazolidonă, gentamicină şi mefenaminat de Na - imobilizate pe un suport din polimeri, formând o peliculă biologic activă, care se aplică în regiunile afectate pentru o durată de la 2...3 ore şi până la 4...5 zile [2]. Also, the method of treating periodontal diseases is known, which includes the administration of a complex of medicinal preparations - trypsin, teritiline, furazolidone, gentamicin and Na mefenaminate - immobilized on a polymer support, forming a biologically active film, which is applied to the affected regions for a period of 2...3 hours and up to 4...5 days [2].
Este cunoscută metoda de tratament al afecţiunilor periodonţiului, care include anestezia, executarea manipulaţiilor chirurgicale, utilizarea preparatelor medicamentoase antiinflamatorii, antimicrobiene şi de stimulare al procesului regenerator. În calitate de preparate antiinflamatorii se utilizează mefenaminat de sodiu de 0,1...0,2% în formă de aplicaţii pe gingie sau fiind introdus în punga parodontală. Preparatul exercită o acţiune antiinflamatoare şi analgezică locală, stimulează regenerarea epiteliului. În parodontologie se utilizează pe larg dimexidul (dimetilsulfoxid) - o substanţă organică cu proprietăţi antiseptică şi antiinflamatoare nespecifică, ce nu provoacă intoleranţă, micşorează edemul inflamator, exercită acţiune de anestezie, manifestă activitate antialergică şi antivirală, pătrunde uşor prin barierele de ţesut şi prin membranele celulelor. Se aplică în stare pură pentru clătirea cavităţii bucale de 0,25%, spălarea pungilor parodontale de 1%, introducerea în pungă pe o meşă de 2%, precum şi pentru diluarea altor substanţe medicamentoase. Se aplică, de asemenea şi alte preparate, cum sunt: soluţie de 0,1% de novoimanină, soluţie de 0,5% de usinat de sodiu, soluţie de 0,05% de clorhexidină bigluconat [3]. The method of treatment of periodontal diseases is known, which includes anesthesia, performing surgical manipulations, using anti-inflammatory, antimicrobial and regenerative process stimulating medicinal preparations. As anti-inflammatory preparations, 0.1...0.2% sodium mefenamine is used in the form of applications on the gum or being introduced into the periodontal pocket. The preparation exerts a local anti-inflammatory and analgesic action, stimulates the regeneration of the epithelium. In periodontology, dimexide (dimethyl sulfoxide) is widely used - an organic substance with non-specific antiseptic and anti-inflammatory properties, which does not cause intolerance, reduces inflammatory edema, exerts anesthetic action, exhibits antiallergic and antiviral activity, easily penetrates through tissue barriers and cell membranes. It is applied in pure form for rinsing the oral cavity at 0.25%, washing periodontal pockets at 1%, inserting into the pocket on a mesh at 2%, as well as for diluting other medicinal substances. Other preparations are also applied, such as: 0.1% solution of novoimanin, 0.5% solution of sodium usinate, 0.05% solution of chlorhexidine bigluconate [3].
Dezavantajele metodelor cunoscute constau în eficacitatea redusă şi de scurtă durată, recidivarea frecventă, administrarea de preparate medicamentoase cu acţiuni adverse. The disadvantages of known methods include low and short-term effectiveness, frequent relapse, and the administration of drugs with adverse effects.
Problema pe care o rezolvă invenţia constă în elaborarea unei metode de tratament al afecţiunilor inflamatorii ale parodonţiului şi mucoasei cavităţii bucale eficiente şi neinvazive cu sporirea efectului terapeutic, reducerea duratei tratamentului, precum şi majorarea termenului de remisie. The problem solved by the invention consists in developing an effective and non-invasive method for treating inflammatory diseases of the periodontium and oral mucosa with increased therapeutic effect, reduced treatment duration, and increased remission period.
Esenţa invenţiei constă în aceea că se efectuează detartrajul dinţilor, se prelucrează mucoasa gingiilor cu ajutorul tampoanelor cu sol. de 1% de hipoclorit de sodiu şi apă oxigenată de 3%, apoi se efectuează clătituri bucale cu 300...500 ml de apă mineralizată sulfuroasă cu o concentraţie de hidrogen sulfurat de 1,08 mg/L, încălzită până la temperatura de 39...40°C, timp de 5...10 min, iar concomitent se administrează per os Magne B6, câte 100 mg, de 3 ori pe zi, cura de tratament fiind de 2...3 săptămâni. The essence of the invention consists in performing the scaling of the teeth, processing the gum mucosa using swabs with 1% sodium hypochlorite solution and 3% hydrogen peroxide, then rinsing the mouth with 300...500 ml of sulfurous mineralized water with a hydrogen sulfide concentration of 1.08 mg/L, heated to a temperature of 39...40°C, for 5...10 min, and simultaneously administering Magne B6 orally, 100 mg, 3 times a day, the treatment course being 2...3 weeks.
Rezultatul invenţiei constă în obţinerea unui rezultat eficient în urma utilizării apei minerale sulfuroase, cu sporirea efectului terapeutic, reducerea duratei tratamentului, precum şi majorarea termenului de remisie. The result of the invention consists in obtaining an effective result from the use of sulfurous mineral water, with increased therapeutic effect, reduced treatment duration, and increased remission period.
Drept evoluţii clinice pozitive în urma utilizării apei minerale medicinale sulfuroase cu o concentraţie de hidrogen sulfurat de până la 1,08 mg/l sunt caracterizate prin următoarele semne: lipsa sensibilităţii dureroase la excitanţii termici, fizici, dispariţia durerii, indicele de igienă a cavităţii orale (Fedorov-Volodkina) se ameliorează, mucoasa gingiei şi papilele gingivale au revenit la culoarea pal-roză, dispariţia sângerărilor gingivale, indicele de extincţie al inflamaţiei: la proba Schiller-Pisarev se prezintă lipsa culorii brune, pungile gingivale se diminuează sau dispar complect în profunzime, se determină retractarea prin aderenţă la rădăcina dinţilor a gingiilor anterior inflamate, se determină stabilizarea dentară şi epitelizarea leziunilor mucoasei orale - mucoasa bucala revenind la culoarea fiziologică. Positive clinical developments following the use of medicinal sulfurous mineral water with a hydrogen sulfide concentration of up to 1.08 mg/l are characterized by the following signs: lack of painful sensitivity to thermal and physical stimuli, disappearance of pain, improvement of the oral cavity hygiene index (Fedorov-Volodkina), return of the gingival mucosa and gingival papillae to a pale pink color, disappearance of gingival bleeding, extinction index of inflammation: absence of brown color in the Schiller-Pisarev test, decrease or complete disappearance of gingival pockets in depth, retraction of previously inflamed gums by adhesion to the tooth root, dental stabilization and epithelialization of oral mucosa lesions are determined - the oral mucosa returning to a physiological color.
Cercetările efectuate au demonstrat că utilizarea apei minerale sulfuroase cu un conţinut sporit de substanţe organice se datorează conţinutului de hidrogen sulfurat şi substanţelor organice. Sulful se absoarbe prin mucoasa orală vindecând unele afecţiuni ale parodonţiului. Apa minerală sulfuroasă medicinală sporeşte circulaţia sanguină la nivelul ţesuturilor afectate, fenomen explicat prin prisma majorării numărului de capilare funcţionale. Drept urmare a sporirii microcirculaţiei locale, are loc absobţia accelerată a apei şi ameliorarea, ulterioară a capacităţilor funcţionale ale orgnismului, prin mobilizarea sistemului imun general şi local al cavităţii bucale. Mecanismele enumerate explică efectul curativ asupra organelor cavităţii bucale, cât şi reabilitarea treptată a ţesuturilor afectate de pe urma unor afecţiuni ale parodonţiului şi mucoasei orale, la utilizarea apei medicinale sulfuroase. Componenţei microbiologice a apei minerale sulfuroase îi revine un rol important de furnizor al substanţelor biologic active, cum ar fi catalaza, proteazele şi aminoacizii, care, la rândul lor, prezintă efecte terapeutice (antiinflamator) de ordin protector la nivelul ţesuturilor lezate ale parodonţiului şi mucoasei orale. De asemenea, glutiţia parţială a apei minerale în timpul clătiturilor (băiţelor) bucale influenţează benefic asupra funcţiilor organelor tubului digestiv. Sulful resorbit intervine în metabolismul general al organismului, echilibrând indicatorii hemodinamici şi biochimici ai sângelui, cu efecte curative locale şi generale asupra organismului. Research has shown that the use of sulfurous mineral water with a high content of organic substances is due to the content of hydrogen sulfide and organic substances. Sulfur is absorbed through the oral mucosa, healing some periodontal diseases. Medicinal sulfurous mineral water increases blood circulation in the affected tissues, a phenomenon explained by the increase in the number of functional capillaries. As a result of the increase in local microcirculation, accelerated water absorption occurs and the subsequent improvement of the functional capacities of the organism occurs by mobilizing the general and local immune system of the oral cavity. The listed mechanisms explain the curative effect on the organs of the oral cavity, as well as the gradual rehabilitation of tissues affected by periodontal diseases and oral mucosa, when using medicinal sulfurous water. The microbiological composition of sulfurous mineral water plays an important role as a supplier of biologically active substances, such as catalase, proteases and amino acids, which, in turn, have therapeutic (anti-inflammatory) protective effects on the damaged tissues of the periodontium and oral mucosa. Also, partial swallowing of mineral water during mouth rinses (baths) has a beneficial effect on the functions of the digestive tract organs. The absorbed sulfur intervenes in the general metabolism of the body, balancing the hemodynamic and biochemical indicators of the blood, with local and general curative effects on the body.
Magneziul reduce exitabilitatea neuronală şi conductibilitatea neuro-musculară, participă la numeroase reacţii enzimatice, iar piridoxina sub acţiunea piridoxal-kinazei este transformată în piridoxal-fosfat şi participă la acţiunea unor enzime necesare pentru funcţionarea normală a ţesutului nervos cu menţinerea excitabilităţii la nivel normal. Magnesium reduces neuronal excitability and neuromuscular conductivity, participates in numerous enzymatic reactions, and pyridoxine under the action of pyridoxal kinase is transformed into pyridoxal phosphate and participates in the action of enzymes necessary for the normal functioning of nervous tissue while maintaining excitability at a normal level.
Metoda se efectuează în modul următor. The method is performed in the following way.
Se prelucrează mucoasa gingiilor cu ajutorul tampoanelor cu sol. de 1% de hipoclorit de sodiu şi apă oxigenată de 3%, apoi se efectuează clătituri bucale cu 300...500 ml de apă mineralizată sulfuroasă cu o concentraţie de hidrogen sulfurat de 1,08 mg/L, încălzită până la temperatura de 39...40°C, timp de 5...10 min, iar concomitent se administrează per os Magne B6, câte 100 mg, de 3 ori pe zi, cura de tratament fiind de 2...3 săptămâni. The gum mucosa is processed using swabs with 1% sodium hypochlorite solution and 3% hydrogen peroxide, then mouth rinses are performed with 300...500 ml of sulfurous mineralized water with a hydrogen sulfide concentration of 1.08 mg/L, heated to a temperature of 39...40°C, for 5...10 min, and at the same time Magne B6 is administered orally, 100 mg, 3 times a day, the treatment course being 2...3 weeks.
Exemplul 1 Example 1
Bolnavul A., 30 ani, s-a adresat cu următoarele acuze: inflamarea şi edemaţierea gingiei, dureri şi sângerarea gingiei în timpul alimentaţiei şi la periaj. Miros fetid din gură. Suferă mai mult de 3 ani. Periodic s-a tratat, dar cu efect de scurtă durată. Obiectiv s-a depistat gingia hiperemiată, edemaţiată şi hipertrofiată, ce acoperă coroana dentară mai mult de 2/3. La atingere gingia este doloră şi sângerează, se depistează pungi gingivale cu o profunzime de 3...4 mm, depuneri dentare sub formă de tartru moale şi dur, miros fetid din gură. S-a stabilit diagnosticul de gingivită hipertrofică generalizată gravă. S-a aplicat metoda revendicată timp de 3 săptămâni în urma căruia au dispărut semnele locale de inflamaţie. Patient A., 30 years old, came to us with the following complaints: inflammation and swelling of the gums, pain and bleeding of the gums during eating and brushing. Bad breath. Suffered for more than 3 years. He was treated periodically, but with a short-term effect. Objectively, hyperemic, swollen and hypertrophied gums were detected, covering more than 2/3 of the dental crown. When touched, the gums are painful and bleed, gingival pockets with a depth of 3...4 mm are detected, dental deposits in the form of soft and hard tartar, bad breath. The diagnosis of severe generalized hypertrophic gingivitis was established. The claimed method was applied for 3 weeks, after which the local signs of inflammation disappeared.
Exemplul 2 Example 2
Bolnavul C, 45 ani, s-a adresat cu acuze la apariţia unor hemoragii gingivale periodice, halenă, mobilitatea dinţilor, îndeosebi a celor frontali, dezgolirea coletului dinţilor şi o sensibilitate sporită în sectorul frontal. Din anamneză, simptomele enumerate au apărut cu aproximativ 9 ani în urmă. La medic nu s-a adresat până acum. În ultimii 3 ani mobilitatea dinţilor a devenit mai pronunţată, la fel şi hemoragiile gingivale. Patient C, 45 years old, complained of periodic gingival bleeding, bad breath, mobility of teeth, especially the front ones, exposure of the tooth necks and increased sensitivity in the frontal sector. From the anamnesis, the listed symptoms appeared approximately 9 years ago. He has not consulted a doctor until now. In the last 3 years, the mobility of teeth has become more pronounced, as have the gingival bleeding.
La examenul obiectiv s-au depistat pungi parodontale cu adâncimea de 4 mm, din care se elimina un exudat sero-purulent. Mobilitatea dinţilor este de gradul II. S-a determinat dezgolirea coletelor şi parţial a rădăcinilor dinţilor. Înălţimea apofizelor alveolare: s-au lăsat neuniform în jos până la 1/3...1/2 din lungimea rădăcinilor. Diagnostic: parodontită cronică generalizată de grad mediu. S-a aplicat metoda revendicată timp de 3 săptămâni. The objective examination revealed periodontal pockets with a depth of 4 mm, from which a sero-purulent exudate was removed. The mobility of the teeth is of the II degree. The exposure of the collars and partial exposure of the roots of the teeth was determined. The height of the alveolar processes: they dropped unevenly down to 1/3...1/2 of the length of the roots. Diagnosis: generalized chronic periodontitis of medium degree. The claimed method was applied for 3 weeks.
La 10 zile după tratamentul efectuat conform metodei revendicate, starea ţesuturilor parodontale s-a ameliorat evident şi s-a manifestat prin reducerea adâncimii pungilor parodontale, dispariţia reacţiei inflamatoare şi a hemoragiilor gingivale. 10 days after the treatment performed according to the claimed method, the condition of the periodontal tissues improved significantly and was manifested by the reduction in the depth of the periodontal pockets, the disappearance of the inflammatory reaction and gingival bleeding.
La examinarea bolnavului peste 3 luni după tratamentul efectuat total au dispărut halena şi hiperestezia în segmentul frontal, s-a micşorat mobilitatea dinţilor. Ameliorarea clinică a fost confirmată prin dinamică pozitivă a indicilor patologici. When examining the patient 3 months after the treatment, bad breath and hyperesthesia in the frontal segment completely disappeared, tooth mobility decreased. Clinical improvement was confirmed by positive dynamics of pathological indices.
1. 1.RU 2146917 C1 2000.03.27 1. 1.RU 2146917 C1 2000.03.27
2. SU 1041116 A1 1983.09.15 2. SU 1041116 A1 1983.09.15
3. Данилевский и др. Заболевания пародонта. Москва, Медицина, 1993, с. 158-186 3. Danilevskii et al. Periodontal diseases. Moscow, Medicine, 1993, p. 158-186
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20190050A MD1406Z (en) | 2019-05-14 | 2019-05-14 | Method for treating inflammatory diseases of periodontium and oral mucosa |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20190050A MD1406Z (en) | 2019-05-14 | 2019-05-14 | Method for treating inflammatory diseases of periodontium and oral mucosa |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1406Y MD1406Y (en) | 2019-12-31 |
| MD1406Z true MD1406Z (en) | 2020-09-30 |
Family
ID=69057881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20190050A MD1406Z (en) | 2019-05-14 | 2019-05-14 | Method for treating inflammatory diseases of periodontium and oral mucosa |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1406Z (en) |
-
2019
- 2019-05-14 MD MDS20190050A patent/MD1406Z/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MD1406Y (en) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS63132820A (en) | Composition for oral cavity | |
| RU2550957C1 (en) | Method of treating chronic generalised periodontitis | |
| RU2470647C1 (en) | Method of treating periodontitis | |
| RU2090181C1 (en) | Medical protection tooth paste | |
| RU2519121C1 (en) | Method of treating periodontitis | |
| RU2162316C1 (en) | Method for treating periodontium diseases | |
| MD1406Z (en) | Method for treating inflammatory diseases of periodontium and oral mucosa | |
| SU1789214A1 (en) | Method of paradontitis treatment | |
| RU2393893C1 (en) | Method of correcting free radical oxidation in oral fluid | |
| RU2661861C1 (en) | Method for treatment of chronic mechanical trauma of the oral mucosa in patients suffering with insulin-dependent diabetes mellitus | |
| RU2147868C1 (en) | Method for treating parodontitis | |
| RU2223088C1 (en) | METHOD FOR TREATING THE CASES OF INFLAMMATION and INFLAMMATORY DESTRUCTIVE PERIODONTIUM DISEASES | |
| RU2158582C1 (en) | Method for curing periodontitis using general treatment approach | |
| RU2201194C2 (en) | Medicinal film "piyavit" for treatment of inflammatory diseases of parodontium | |
| RU2258546C1 (en) | Pathogenic microflora suppression method | |
| RU2214217C1 (en) | Method for treating parodontitis | |
| RU2693678C1 (en) | Method of treating chronic generalized periodontitis | |
| RU2549445C1 (en) | Method of treating periodontitis and oral mucosal diseases associated with helicobacter infection, and method for using it | |
| RU2785010C1 (en) | Method for treating moderate periodontitis in patients after a coronavirus infection | |
| RU2772298C1 (en) | Method for treatment of chronic catarrhal gingivitis using antiseptic composition | |
| RU2830816C2 (en) | Use of phospholipid emulsion containing effective amount of dihydroquercetin, lecithin and glycine for treating chronic and inflammatory oral diseases | |
| RU2254859C1 (en) | Method for treating parodontitis | |
| RU2134098C1 (en) | Method for treating inflammatory periodontium diseases | |
| RU2772293C1 (en) | Method for treatment of chronic aphthous stomatitis | |
| RU2429859C1 (en) | Method of treating periodontitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |